Axis Granted Review of Arecont Multi-Imager: 'More Likely Than Not' 'Unpatentable'

By Brian Karas, Published Jan 09, 2018, 09:25am EST

In 2016, Arecont publicly threatened Axis [link no longer available] with infringing on their multi-imager patent.

In 2017, Axis responded by filing a challenge in US court for Arecont's patent.

Now, the USPTO has seen merit in Axis' claim, granting their request for a post grant review, which is done on the basis it is "more likely than not" that at least one claim of a patent is actually unpatentable.

In this update, we examine the current status of the case, timeline, steps to a final resolution, and how losing this patent could affect Arecont.

Summary ** ***** ******* ********

** * ******** ****** ** *** patent ******, *** ** *** 17 ****** **** ** Arecont's ******** ****** **** deemed ** ** *********** unpatentable. **** ******** ** based ** ****** ** prior *** *** ***** evidence ******** ** **** in ***** *********:

***** ** **** ********, the ****** ********* ***** ** to * *****, *** ultimately * ***** ******** that **** ******, ** invalidate, *******'* ****** ******.

Axis ************ *********

**** ****** *******'* ****** is ******* ******* **** ***** **/******* 103, ***** ****** *** approach ** "*******" ***** on ***** ***/******** *******. **** submitted ** ******** ******* with ******** ** **** prior ***, ******* ******** challenges ** **** ** the ** ****** ** patentability ******* **** ** its ******* ****** ***********. Arecont ***** ******** *****-****** ****** ** April ****. **** ** ****' claims ** ***** *** include:

******* **** *** ****** *** "obvious" ** * "******* artisan", ** ****** *********** in ****** ******** ** indicate **** *** ****** concept **** ***** **** been ******* ** ** any ****** ******* ** the *** ** ***** such ******* (**** **** companies ********* ***** *** use "*********" ********* *** such ********). **** ***** it ************, ******* *** design ** ********* *** unique ****** ** ******* a ****** *** ***** have **** ********* ** any ********* ********.

Next *****

********** ***** ******** * ****** ** 7 *** ***** *** deadlines *** **** **** and ******* ** ******* the ****** *******, *** to ****** ********** ********* or ********** ** ***** claims. ***** *** ***** and ***** ****** ******** ************* for ******* ** ****** their ******, *** *** Axis ** ******* ** any ********** ****** ** information ******** ** *******.

*** ** *** *** dates *** ** ********** interest:

*** **** *: ******** 27, **** - ******* has ***** **** **** to ******* ***** ******** to *** ******** ** file *** ******* ** amend *** ******. ** far, **** **** *** provided *** ********** ********, though **** **** ******* weeks **** ** ** so. *******'* ********, ** lack ** ***, **** likely *** *** ****, and ************, *** *** rest ** *** *******. Not ****** * ******** is * ****-********* **** the ****** ** *** valid.

*** **** *: ****** 21, **** - ***** oral ********* **** ** front ** ****** ****** panel, **** * ******** being ****** ** ** shortly ***** **** ****.

Arecont ********

******* ******* *** ********* statement ** ******** ** this **** ********** ** trial:

*********, ** *** ******* to ******* *** ******* positioning ********* *** *******.  However, * **** ** comment ********* *** ******** litigation.

Impact ** ****** ***********

****** ***** ****** *********** could ********** ****** *** overall ********* ** *** company, ************ ** ******* intends ** **** * new ***** ***** ***** ******** ********* **** **** through. ****, **** ***** eliminate *** *********** ** Arecont ******* ****** ******* revenue ******** ** **** Avigilon *** **** ***** over *** **** *** years.

*******, * **** ** the ****** ** ******** ** put *** ******* ** significant ********** **** ** competitors ******* *********** ** their *****-****** ****** *****. Several ***** ********* **** already ******* *****-****** ******* (e.g.************,********************). *******, *******' *** quality ******** *** **** reputation ******** ** **** it ******* *** **** larger ****** ** *** multi-imager *****.

***** *** ***** ****** invalidation ******** ***** **** Arecont's ***** ****-*** / exit ********, *** ****** in **** ***** ******* means **** *** ****** impact ****** ** *****.

Comments (0)

Read this IPVM report for free.

This article is part of IPVM's 6,817 reports, 914 tests and is only available to members. To get a one-time preview of our work, enter your work email to access the full article.

Already a member? Login here | Join now
Loading Related Reports